Fibrinolysis for acute myocardial infarction in the elderly patient: Is it effective or too dangerous?

American Journal of Geriatric Cardiology

Volumn 7, Issue 1, 1998, Pages 22-27

  Straznicky, Ivan T ^a   French, John K ^a   White, Harvey D ^a   Califf, Robert M ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; ELDERLY CARE; FIBRINOLYTIC THERAPY; HUMAN;

EID: 0031985307     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stevenson R, Ranjadayalan K, Wilkinson P, et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J. 1993;307:349-353.
2. White HD, Barbash GI, Califf RM, et al. Age and Outcome With Contemporary Thrombolytic Therapy. Results From the GUSTO 1 Trial. Circulation. 1996;94:1826-1833.
3. Sumita D, et al. Geriatric patients with acute myocardian infarction: Cardiac risk factor profiles, presentation, thrombolysis, coronary interventions and prognosis. Am Heart J. 1996; 131: 710-715.
4. Ryan T, et al. Guidelines for the Management of Patients With Acute Myocardial Infarction. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-428.
5. Gurwitz JH, Goldberg RJ, Gore JM. Coronary Thrombolysis for the Elderly? JAMA. 1991;265:1720-1723.
6. Hunink MG, Golman L, Tosteson AN, et al. The Recent Decline in Mortality From Coronary Heart Disease, 1980-1990. The Effect of Secular Trends in Risk Factors and Treatment. JAMA. 1997;277:535-542.
7. Manolio TA, Furberg CD. Age as a Predictor of Outcome: What role does it play? Am J Med. 1992;92:1-5.
8. Maggioni AP, Maseri A, et al, on behalf of GISSI 2. Age related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med. 1993;329: 1442-1448.
9. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;I:397-402.
10. Fibrinolytic Therapy Trialists' (FTT) Collaborative group. Indications for fibrinolytic therapy in suspected myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomosed trials of more than 1000 patients. Lancet. 1994;343:311-322.
11. Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-1 Investigators. Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction. Results From an International Trial of 41, 021 Patients. Circulation. 1995;91:1659-1668.
12. Rogers WJ, Bowlby LJ, et al.Treatment of Myocardial Infarction in the United States (1990 to 1993). Observations From the National registry of Myocardioal Infarction. Circulation. 1994;90:2103-2114.
13. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol. 1991;18:657-662.
14. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J. 1996;312:1637-1641.
15. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
16. Lesnefsky EJ, Lundergan CF, Hodgson JM, et al. Increased Left Ventricular Dysfunction in Elderly Patients Despite Successful Thrombolysis: The GUSTO 1 Angiographic Experience. J Am Coll Cardiol. 1996;28:331-337.
17. AIMS trial study group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
18. Wilcox RG, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;II:525-530.
19. ISIS 2 (Second International Sudy of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS 2. Lancet. 1988;:349-360.
20. Gore JM, Granger CB, Simoons ML, et al. Stroke After Thrombolysis. Mortality and Functional Outcomes in the GUSTO 1 Trial. Circulation. 1995;92:2811-2818.
21. Maggioni PM, Franzosi MG, Santoro E, et al. The GISSI 2 and International Study Group. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med. 1992;327:1-6.
22. ISIS 3 (Third International Study of Infarct Survival) Collaborative Group. ISIS 3: A randomised comparison streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
23. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992;327:7-13.
24. Mark DB, Hlatky MA, Califf RM, et al. Cost Effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:18-24.